Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...

Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Food companies are capitalizing on the GLP-1 trend, offering high-protein, portion-controlled meals. But are they meeting ...

Greenland’s Prime Minister, Múte B. Egede, announced that the semi-autonomous Danish territory will hold a general election on March 11. The announcement comes amid increasing global attention, ...